



COVID-19, Parkinson's Disease and Other Neurodegenerative Disorders

Guest Editors:

Prof. Dr. Lars Tönges

Department of Neurology, Ruhr-Universität Bochum, Bochum, Germany

Prof. Dr. Stephan Klebe

Department for Neurology, University Hospital Essen, Essen, Germany

Deadline for manuscript submissions:

closed (15 March 2022)

Message from the Guest Editors

The COVID-19 pandemic is currently affecting almost every area of our daily lives. Neurological patients are experiencing a drastic disruption in the provision of medical care. The strong changes also apply to Parkinson's disease and other neurodegenerative disorders. Of note, symptoms of COVID-19 patients and patients with neurodegenerative disease partially overlap, such as olfactory disorders, and similar pathophysiological processes of symptom development are described up to the discussion of an increased neuronal vulnerability induced by COVID-19. How far COVID-19 specifically affects or exposes these patients to an increased risk is not well understood. However, the need to adapt our services for patients with neurodegenerative disease has also resulted in improvements. Many of these achievements will remain highly valued even after the COVID-19 pandemic and will improve our practical work and treatment performance. In this Special Issue, we would like to present important findings on COVID-19, Parkinson's and other neurodegenerative diseases in a series of publications so that we can jointly effectively master the challenges associated with COVID-19.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, CAPlus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Brain Sciences Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/brainsci
brainsci@mdpi.com
[X@BrainSci_MDPI](https://twitter.com/BrainSci_MDPI)